Literature DB >> 9738043

Outbreak of Pseudomonas fluorescens bacteremia among oncology patients.

P R Hsueh1, L J Teng, H J Pan, Y C Chen, C C Sun, S W Ho, K T Luh.   

Abstract

From 7 to 24 March 1997, four patients developed Pseudomonas fluorescens bacteremia at the hospital; one on the oncology ward and the other three in the chemotherapy room. These patients all had underlying malignancies and had the Port-A-Cath (Smiths Industries Medical Systems, Deltec, Inc., St. Paul, Minn.) implants. Three patients had primary bacteremia, and one had Port-A-Cath-related infection. None of these patients had received a blood transfusion before the episodes of bacteremia. All patients recovered: two received antimicrobial agents with in vitro activity against the isolates, and the other two did not have any antibiotic treatment. A total of eight blood isolates were recovered from these patients during the febrile episodes that occurred several minutes after the infusion of chemotherapeutic agents via the Port-A-Cath. These isolates were initially identified as P. fluorescens or Pseudomonas putida (four), Burkholderia (Ralstonia) pickettii (three), and a non-glucose-fermenting gram-negative bacillus (one) by routine biochemical methods and the Vitek GNI card. These isolates were later identified as P. fluorescens on the basis of the characteristic cellular fatty acid chromatogram and the results of supplemental biochemical tests. The identification of identical antibiotypes by the E test and the random amplified polymorphic DNA patterns generated by arbitrarily primed PCR of the isolates showed that the outbreak was caused by a single clone of P. fluorescens. Surveillance cultures of the possibly contaminated infusion fluids and disinfectants, which were performed 7 days after recognition of the last infected patient, failed to isolate P. fluorescens. This report of a small outbreak caused by P. fluorescens suggests that timely, accurate identification of unusual nosocomial pathogens is crucial for early initiation of an epidemiological investigation and timely control of an outbreak.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738043      PMCID: PMC105087     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Outbreak of scarlet fever at a hospital day care centre: analysis of strain relatedness with phenotypic and genotypic characteristics.

Authors:  P R Hsueh; L J Teng; P I Lee; P C Yang; L M Huang; S C Chang; C Y Lee; K T Luh
Journal:  J Hosp Infect       Date:  1997-07       Impact factor: 3.926

2.  Multicenter in vitro evaluation of SM-7338, a new carbapenem.

Authors:  R N Jones; K E Aldridge; S D Allen; A L Barry; P C Fuchs; E H Gerlach; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

3.  Tests for detecting degradation of gelatin: comparison of five methods.

Authors:  M J Pickett; J R Greenwood; S M Harvey
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

4.  Identification of clinical isolates of gram-negative nonfermentative bacteria by an automated cellular fatty acid identification system.

Authors:  G J Osterhout; V H Shull; J D Dick
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

5.  Contamination during in vitro processing of bone marrow for transplantation: clinical significance.

Authors:  H M Lazarus; M Magalhaes-Silverman; R M Fox; R J Creger; M Jacobs
Journal:  Bone Marrow Transplant       Date:  1991-03       Impact factor: 5.483

6.  A fatal transfusion reaction associated with blood contaminated with Pseudomonas fluorescens.

Authors:  J Scott; F E Boulton; J R Govan; R S Miles; D B McClelland; C V Prowse
Journal:  Vox Sang       Date:  1988       Impact factor: 2.144

7.  Blood transfusion-associated Pseudomonas fluorescens septicaemia: is this an increasing problem?

Authors:  A E Murray; C A Bartzokas; A J Shepherd; F M Roberts
Journal:  J Hosp Infect       Date:  1987-05       Impact factor: 3.926

8.  In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity.

Authors:  N Watanabe; K Katsu; M Moriyama; K Kitoh
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

9.  Incidence and identification of Pseudomonas fluorescens and Pseudomonas putida in the clinical laboratory.

Authors:  D J Blazevic; M H Koepcke; J M Matsen
Journal:  Appl Microbiol       Date:  1973-01

10.  Pseudobacteremia due to Pseudomonas fluorescens.

Authors:  A E Simor; J Ricci; A Lau; R M Bannatyne; L Ford-Jones
Journal:  Pediatr Infect Dis       Date:  1985 Sep-Oct
View more
  29 in total

1.  Presumed pseudobacteremia outbreak resulting from contamination of proportional disinfectant dispenser.

Authors:  E Siebor; C Llanes; I Lafon; A Ogier-Desserrey; J M Duez; A Pechinot; D Caillot; M Grandjean; N Sixt; C Neuwirth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-03       Impact factor: 3.267

2.  Bacteremia or pseudobacteremia? Review of pseudomonas fluorescens infections.

Authors:  Takeshi Nishimura; Kenji Hattori; Akihiko Inoue; Taiji Ishii; Tetsuya Yumoto; Kohei Tsukahara; Astunori Nakao; Satoshi Ishihara; Shinichi Nakayama
Journal:  World J Emerg Med       Date:  2017

3.  Type III secretion system and virulence markers highlight similarities and differences between human- and plant-associated pseudomonads related to Pseudomonas fluorescens and P. putida.

Authors:  Sylvie Mazurier; Annabelle Merieau; Dorian Bergeau; Victorien Decoin; Daniel Sperandio; Alexandre Crépin; Corinne Barbey; Katy Jeannot; Maïté Vicré-Gibouin; Patrick Plésiat; Philippe Lemanceau; Xavier Latour
Journal:  Appl Environ Microbiol       Date:  2015-01-30       Impact factor: 4.792

4.  Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis.

Authors:  Takashi Obata; Yoshiyuki Goto; Jun Kunisawa; Shintaro Sato; Mitsuo Sakamoto; Hiromi Setoyama; Takahiro Matsuki; Kazuhiko Nonaka; Naoko Shibata; Masashi Gohda; Yuki Kagiyama; Tomonori Nochi; Yoshikazu Yuki; Yoshiko Fukuyama; Akira Mukai; Shinichiro Shinzaki; Kohtaro Fujihashi; Chihiro Sasakawa; Hideki Iijima; Masatoshi Goto; Yoshinori Umesaki; Yoshimi Benno; Hiroshi Kiyono
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-01       Impact factor: 11.205

5.  Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen.

Authors:  Bo Wei; Tiffany Huang; Harnisha Dalwadi; Christopher L Sutton; David Bruckner; Jonathan Braun
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

Review 6.  Microbiology, genomics, and clinical significance of the Pseudomonas fluorescens species complex, an unappreciated colonizer of humans.

Authors:  Brittan S Scales; Robert P Dickson; John J LiPuma; Gary B Huffnagle
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

7.  Spread of Pseudomonas fluorescens due to contaminated drinking water in a bone marrow transplant unit.

Authors:  Vanessa Wong; Katrina Levi; Buket Baddal; Jane Turton; Tim C Boswell
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

8.  Transplantation-associated long-term immunosuppression promotes oral colonization by potentially opportunistic pathogens without impacting other members of the salivary bacteriome.

Authors:  Patricia I Diaz; Bo-Young Hong; Jorge Frias-Lopez; Amanda K Dupuy; Mark Angeloni; Loreto Abusleme; Evimaria Terzi; Effie Ioannidou; Linda D Strausbaugh; Anna Dongari-Bagtzoglou
Journal:  Clin Vaccine Immunol       Date:  2013-04-24

9.  Melioidosis: an emerging infection in Taiwan?

Authors:  P R Hsueh; L J Teng; L N Lee; C J Yu; P C Yang; S W Ho; K T Luh
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883

10.  Involvement of a phospholipase C in the hemolytic activity of a clinical strain of Pseudomonas fluorescens.

Authors:  Gaelle Rossignol; Annabelle Merieau; Josette Guerillon; Wilfried Veron; Olivier Lesouhaitier; Marc G J Feuilloley; Nicole Orange
Journal:  BMC Microbiol       Date:  2008-10-30       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.